Differential Expression of Steroid 5α-Reductase Isozymes and Association with Disease Severity and Angiogenic Genes Predict Their Biological Role in Prostate Cancer
June 2010
in “
Endocrine Related Cancer
”
TLDR SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
The study examined the roles of steroid 5α-reductase isozymes, SRD5A1 and SRD5A2, in prostate cancer (PC) using samples from 62 patients. It found that SRD5A1 was associated with more advanced cancer stages and higher Gleason scores, while SRD5A2 correlated with VEGF expression. Dutasteride, which inhibits both isozymes, was more effective in reducing tumor cell viability than finasteride, which only inhibits SRD5A2. Despite treatment, angiogenic genes remained active, indicating potential resistance. The study highlighted SRD5A1's predominance in advanced PC and suggested further exploration of these isozymes as therapeutic targets.
